Miami Beach, FL — March 3, 2026 — Leads & Copy — Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced today that management will participate in a fireside chat at The Citizens Life Sciences Conference on Tuesday, March 10, 2026, at 10:45 a.m. ET in Miami Beach, FL.
The clinical-stage biotechnology company is dedicated to creating small molecule drugs for viral infections and immunological diseases.
A live webcast of the event will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website.
A replay of the webcast will be available following the presentation and will be archived for at least 30 days.
Enanta is using its chemistry-driven approach and drug discovery capabilities to become a leader in discovering and developing small molecule drugs for viral infections and immunological diseases. Enanta’s clinical programs are focused on respiratory syncytial virus (RSV), and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, with KIT, STAT6, and MRGPRX2 inhibition.
Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations.
Source: Enanta Pharmaceuticals, Inc.
